Free Trial
NASDAQ:DAWN

Day One Biopharmaceuticals Q4 2023 Earnings Report

Day One Biopharmaceuticals logo
$7.59 0.00 (0.00%)
Closing price 08/28/2025 04:00 PM Eastern
Extended Trading
$7.58 0.00 (-0.07%)
As of 08/28/2025 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Day One Biopharmaceuticals EPS Results

Actual EPS
-$0.64
Consensus EPS
-$0.57
Beat/Miss
Missed by -$0.07
One Year Ago EPS
N/A

Day One Biopharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Day One Biopharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, February 26, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Day One Biopharmaceuticals' Q3 2025 earnings is scheduled for Wednesday, October 29, 2025, with a conference call scheduled at 4:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Day One Biopharmaceuticals Earnings Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.tc pixel
See More Day One Biopharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Day One Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Day One Biopharmaceuticals and other key companies, straight to your email.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals (NASDAQ:DAWN), a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

View Day One Biopharmaceuticals Profile

More Earnings Resources from MarketBeat